PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Melevodopa→

Melevodopa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
7101-51-1
Molecular formula
C10H13NO4
Molecular weight
211.21 g/mol
Drug class
Levodopa prodrugmethyl ester of L-DOPA
Mechanism of action
Melevodopa is the methyl ester of levodopa. Following hydrolysis to levodopa, it enters the brain via amino-acid transport and is decarboxylated by aromatic L-amino-acid decarboxylase to dopamine, replenishing deficient striatal dopaminergic signalling.
Indications / reported uses
  • Investigated and used in some countries as a rapidly absorbed levodopa form for treatment of Parkinson’s disease, generally in combination with a peripheral dopa-decarboxylase inhibitor. Product availability and authorisation are jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/23497 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/levodopa · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Melevodopa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Melevodopa Permitted Daily Exposure (PDE) report (the Melevodopa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Melevodopa Occupational Exposure Limit (OEL) report (the Melevodopa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.